Prescient Therapeutics Drives PTX-100 Development with New Capital Raise

3 min read | July 29, 2025 05:56 PM AEST | By Team Kalkine Media

Prescient Therapeutics Drives PTX-100 Development with New Capital Raise — Image source: Shutterstock

Capital Raised to Support PTX-100 Clinical Progression

The capital secured through the SPP is allocated toward accelerating the development of PTX-100, which is being positioned as a novel treatment candidate in oncology. Funds raised from shareholders are directed at enabling the company to maintain momentum through its Phase 2 clinical activities.

With additional support through a subsequent placement for sophisticated and professional participants, Prescient aims to expand access beyond the original SPP cap. This structure allowed wider participation from stakeholders seeking a greater role in funding the development initiative.

Share Placement Matches SPP Pricing

The company issued shares in the follow-on placement at a price consistent with the SPP offering. The alignment of pricing indicates a cohesive approach in managing shareholder equity while accommodating broader participation. The placement also utilised capacity available under the listing rules, avoiding the need for a shareholder meeting.

Prescient entered a trading halt to execute the placement efficiently, ensuring continuity in its operational plans without delays in regulatory obligations. The new funding is expected to supplement existing resources, giving the company greater flexibility in executing its strategic milestones.

Leadership Optimism and Forward Clinical Strategy

Prescient’s leadership acknowledged the supportive response to the funding initiative, highlighting its role in reinforcing the company’s clinical agenda. PTX-100 remains a central asset in the company’s pipeline, with the upcoming clinical stages representing a critical juncture in its development path.

With its latest financing round, the company continues to advance its commercial development timeline while navigating the requirements of regulatory frameworks. Updates regarding allocation and clinical progress are anticipated as the funding is deployed into trial operations.

What is the purpose of Prescient’s capital raise?

Prescient Therapeutics conducted the share purchase plan to support the clinical development of PTX-100 through further trial stages.

How were shares allocated to different participants?

Initial shares were offered through the SPP, followed by a placement to sophisticated and professional participants at the same price.

What is PTX-100?

PTX-100 is Prescient’s lead therapeutic candidate, focused on oncology treatment and currently progressing through clinical trials.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.